Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Accured Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Change in Accured Expenses for 12 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 191.06% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, up 311.14% year-over-year, with the annual reading at $3.2 million for FY2025, 311.14% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $1.9 million at ImmunityBio, down from $5.5 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $18.6 million in Q1 2023, with the low at -$19.5 million in Q4 2023.
  • Average Change in Accured Expenses over 5 years is $882450.0, with a median of $2.6 million recorded in 2024.
  • The sharpest move saw Change in Accured Expenses surged 675.33% in 2022, then crashed 519.36% in 2023.
  • Over 5 years, Change in Accured Expenses stood at $4.6 million in 2021, then tumbled by 169.13% to -$3.2 million in 2022, then plummeted by 519.36% to -$19.5 million in 2023, then soared by 89.17% to -$2.1 million in 2024, then surged by 191.06% to $1.9 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $1.9 million, $5.5 million, and $8.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.